Evome Medical Technologies (Evome Medical Technologies) Debt-to-EBITDA : -0.47 (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Evome Medical Technologies Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Evome Medical Technologies's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $13.42 Mil. Evome Medical Technologies's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $4.98 Mil. Evome Medical Technologies's annualized EBITDA for the quarter that ended in Dec. 2023 was $-39.61 Mil. Evome Medical Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.46.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Evome Medical Technologies's Debt-to-EBITDA or its related term are showing as below:

LNDZF' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -3.25 Med: -1.94 Max: -0.6
Current: -2.94

During the past 11 years, the highest Debt-to-EBITDA Ratio of Evome Medical Technologies was -0.60. The lowest was -3.25. And the median was -1.94.

LNDZF's Debt-to-EBITDA is ranked worse than
100% of 434 companies
in the Medical Devices & Instruments industry
Industry Median: 1.23 vs LNDZF: -2.94

Evome Medical Technologies Debt-to-EBITDA Historical Data

The historical data trend for Evome Medical Technologies's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evome Medical Technologies Debt-to-EBITDA Chart

Evome Medical Technologies Annual Data

Trend

Dec14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

Dec23

Debt-to-EBITDA

Get a 7-Day Free Trial

-3.25

-2.94

Evome Medical Technologies Quarterly Data
	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Mar23	Jun23	Sep23	Dec23
Debt-to-EBITDA	Get a 7-Day Free Trial															-5.48	-9.13	13.84	1.41	-0.47

Competitive Comparison of Evome Medical Technologies's Debt-to-EBITDA

For the Medical Devices subindustry, Evome Medical Technologies's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Evome Medical Technologies's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Evome Medical Technologies's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Evome Medical Technologies's Debt-to-EBITDA falls into.

Evome Medical Technologies Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Evome Medical Technologies's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(13.422	+	4.982)	/	-6.259
	=	-2.94

Evome Medical Technologies's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA	=	Total Debt			/	EBITDA
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	EBITDA
	=	(13.422	+	4.982)	/	-39.612
	=	-0.46

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.

Evome Medical Technologies (OTCPK:LNDZF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Evome Medical Technologies Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Evome Medical Technologies's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.